Claims

1. Use of ~~one or more of~~ uridine monophosphate (UMP) ~~and cytidine, or salts, phosphates, acyl derivatives or esters thereof~~ in the manufacture of a composition for treating~~,~~ a non-demented elderly subject suffering from ~~preventing or reducing the risk of occurrence of white matter lesions,~~ white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease ~~in elderly not suffering from a neurodegenerative disorder, preferably non-demented elderly and elderly not suffering from Alzheimer's Disease.~~, wherein the elderly subject is a human subject of at least 50 years of age, wherein the composition is to be administered to the elderly subject daily, and wherein the composition comprises:
   (a) 500 – 5000 mg docosahexaenoic acid (DHA),
   (b) 200 – 600 mg choline,
   (c) 400 – 800 mg UMP, and
   (d) 200 – 600 µg folic acid.

2. Use according to claim 1, wherein the composition comprises, per day:
   (a) 900 – 1500 mg docosahexaenoic acid (DHA),
   (b) 200 – 600 mg choline,
   (c) 400 – 800 mg UMP, and
   (d) 200 – 600 µg folic acid.

~~2. Use according to claim 1, said composition further comprising a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof.~~

3. Use according to any one of the preceding claims, for controlling, reducing or suppressing Nogo-A protein levels.

~~4. Use according to any one of the preceding claims, said composition further comprising at least one of:~~

~~choline, or salts or esters thereof ; or~~

~~at least one vitamin B selected from the group of vitamin B6, vitamin B12 and vitamin B9, or equivalents thereof, preferably comprising vitamin B6, B9 and B12,~~

~~5~~4. Use according to any one of the preceding claims, said composition further ~~comprising at least one vitamin B selected from the group of vitamin B6, vitamin B12 and vitamin B9, or equivalents thereof, preferably~~ comprising vitamin B6, B9 and B12.

~~6. Use according to any one of the preceding claims, said composition comprising 9 to 300 mg/100 kJ DHA+EPA+DPA, preferably DHA+EPA per day.~~

~~7. Use according to any one of the preceding claims , said composition comprising 1.5 to 130 mg / 100 kJ of one or more of uridine, cytidine, or salts, phosphates or esters thereof, calculated as uridine and cytidine.~~

~~8. Use according to any one of the preceding claims, said composition comprising 1 to 300 mg / 100 kJ of choline, or salts or esters thereof, calculated as choline.~~

~~9~~5. Use according to any one of the preceding claims, said composition further comprising one or more selected from the group consisting of vitamin C or its equivalents, vitamin E or its equivalents, and selenium.

~~10~~6. Use according to any one of the preceding claims, said composition further comprising at least one phospholipid.

~~11~~7. Use according to any one of the preceding claims, said composition being an aqueous composition comprising, per daily dosage or per 100 ml of liquid:
100 – 500 mg EPA,
900 – 1500 mg DHA,
50 – 600 mg phospholipids,
200 – 600 mg choline,
400 – 800 mg UMP (uridine monophosphate),

20 – 60 mg vitamin E (alpha-TE),
60 – 100 mg vitamin C,
40 – 80 µg selenium,
1 – 5 µg vitamin B12,
0.5 – 3 mg vitamin B6, and
200 – 600 µg folic acid.

8. Use according to any one of the preceding claims, wherein said composition is to be enterally administered to the elderly subject at least one time per day for a period of at least 3 weeks.

9. Use of uridine monophosphate (UMP) in the manufacture of a composition for treating an elderly subject suffering from white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease, wherein the elderly subject is a human subject of at least 50 years of age, wherein the composition is to be administered to the subject daily, wherein the composition comprises:
(a) 500 – 5000 mg docosahexaenoic acid (DHA),
(b) 200 – 600 mg choline,
(c) 400 – 800 mg UMP, and
(d) 200 – 600 µg folic acid,
wherein the subject does not suffer from Alzheimer's Disease.

10. Use according to claim 9, wherein the composition is to be administered to the elderly subject daily, wherein the composition comprises:
(a) 900 – 1500 mg docosahexaenoic acid (DHA),
(b) 200 – 600 mg choline,
(c) 400 – 800 mg UMP, and
(d) 200 – 600 µg folic acid.

11. Use according to claim 9 or 10, for controlling, reducing or suppressing Nogo-A protein levels.

12. Use according to any one of claims 9-11, said composition further comprising vitamin B6, B9 and B12.

13. Use according to any one of claims 9-12, said composition further comprising one or more selected from the group consisting of vitamin C or its equivalents, vitamin E or its equivalents, and selenium.

14. Use according to any one of claims 9-13, said composition being an aqueous composition comprising, per daily dosage or per 100 ml of liquid:
100 – 500 mg EPA,
900 – 1500 mg DHA,
50 – 600 mg phospholipids,
200 – 600 mg choline,
400 – 800 mg UMP (uridine monophosphate),
20 – 60 mg vitamin E (alpha-TE),
60 – 100 mg vitamin C,
40 – 80 µg selenium,
1 – 5 µg vitamin B12,
0.5 – 3 mg vitamin B6, and
200 – 600 µg folic acid.

~~12. Use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for controlling, reducing or suppressing Nogo-A protein levels in elderly not suffering from a neurodegenerative disorder, preferably non-demented elderly.~~

~~13. A composition for use in treating, preventing or reducing the risk of occurrence of white matter lesions, white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease and/or for use in controlling, reducing or suppressing Nogo-A protein levels in elderly not suffering from a neurodegenerative disorder, preferably non-demented elderly and elderly not suffering from Alzheimer's Disease, said composition comprising one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and~~

~~optionally a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof.~~

* * * * *